Introduction
============

*Burkholderia pseudomallei*, the etiological agent of melioidosis, is a saprophytic Gram negative bacterium endemic to many tropical and subtropical regions of the world although much of the disease and its investigation has historically been confined to Northern Australia and regions of SE Asia, notably NE Thailand, Singapore, and Malaysia (Cheng and Currie, [@B3]; Wiersinga et al., [@B40]; Currie et al., [@B10]). Partially because of its large genome and diverse repertoire of metabolic functions *B. pseudomallei* can survive hostile conditions and is resilient to many antimicrobial agents, including antibiotics (Holden et al., [@B17]). This makes choosing effective therapeutic strategies difficult. In the past three decades even the most effective treatment could not prevent a mortality rate of 74% (White et al., [@B39]). Clinical outcomes improved steadily with implementation of new therapies but the real breakthrough was achieved with the introduction of ceftazidime, an extended-spectrum cephalosporin, which halved the mortality rate compared to the traditional multidrug therapy of chloramphenicol, doxycycline, and trimethoprim--sulfamethoxazole (White et al., [@B39]). Currently recommended melioidosis treatment involves acute phase therapy followed by a lengthy eradication therapy. Initial parenteral therapy involves ceftazidime or a carbapenem for a minimum of 10--14 days and longer (4--8 weeks) for deep-seated infection. This regimen may be supplemented with trimethoprim--sulfamethoxazole given orally for treatment of patients with neurologic, prostatic, bone, or joint melioidosis. Oral eradication therapy is trimethoprim--sulfamethoxazole with or without doxycycline for at least 3--6 months (Peacock et al., [@B28]).

Because of the pivotal role that β-lactams play in the acute phase treatment of melioidosis emergence of resistance, though still considered rare, is of concern. It is believed that *B. pseudomallei*'s resistance to β-lactams is due to chromosomally encoded β-lactamases (Livermore et al., [@B22]; Godfrey et al., [@B14]). These include a number of Ambler Class A, B, and D β-lactamases that are encoded by the K96243 and other *B. pseudomallei* genomes (Holden et al., [@B17]). The *penA* gene (K96243 gene *BPSS0946* found on chromosome II; Figure [1](#F1){ref-type="fig"}) encodes a Class A β-lactamase (Cheung et al., [@B5]; Tribuddharat et al., [@B35]). This gene is present and expressed in prototype *B. pseudomallei* strains. PenA confers resistance to numerous β-lactam antibiotics when expressed in *Escherichia coli* (Cheung et al., [@B5]; Tribuddharat et al., [@B35]) and several reports described a role of this enzyme in acquired ceftazidime resistance in patients treated with this antibiotic (Godfrey et al., [@B14]; Tribuddharat et al., [@B35]; Sam et al., [@B31]). Mutations identified in clinical strains included a C69Y substitution leading to high-level ceftazidime resistance (Sam et al., [@B31]), a P167S substitution leading to medium-level ceftazidime resistance (Tribuddharat et al., [@B35]) and a S72F mutation that led to resistance to clavulanic acid (Tribuddharat et al., [@B35]). A Class D Oxa-57 β-lactamase has been studied *in vitro* but its role in clinically significant β-lactam resistance remains unclear (Keith et al., [@B20]).

![**Genomic organization of the *B*. pseudomallei *penA* region**. The genes and gene order are from sequenced strain K96243 (GenBank accession number NC_006351). The *penA* region encodes two LysR-type regulators (BPSS0944 and BPSS0948) and a putative peptidase (BPSS0945). The names of the mutants harboring gene deletion and extents of deleted sequences are shown above each gene. The putative PenA twin arginine translocase (TAT) signal sequence is shown below the *penA* gene with the two conserved arginine residues shown in red letters. Arrows indicate amino acid substitutions, R7K and R8A, in the TAT-signal sequence and the names of the mutants are shown next to the respective amino acids replacing the original arginines.](fmicb-02-00139-g001){#F1}

While *B. pseudomallei* PenA β-lactamase has been studied in some detail, previously published reports suffered until recently from some unavoidable shortcomings. First, many mutations contributing to clinically significant β-lactam resistance were identified in genetically largely intractable clinical isolates. Thus, it remained unclear whether the mutations were solely responsible for causing the observed resistance. Second, because methods for genetic manipulation of *B. pseudomallei* were rather rudimentary until recently, most studies involved expression of putative β-lactamase enzymes in *E. coli*. Third, United States Select Agent and recombinant DNA regulations, as well as dual use concerns, do complicate studies of clinically significant antibiotic resistance mechanisms. To address shortcomings of previous studies, we employed state-of-the-art Select Agent-compliant genetic and biochemical methods and a defined genetic background of a Select Agent excluded *B. pseudomallei* strain, where applicable, to study the contribution of PenA to *B. pseudomallei*'s resistance to clinically significant β-lactam antibiotics. The studies also revealed that PenA is secreted via the twin arginine translocase system and that its expression in prototype strains does not seem to be regulated by local transcriptional regulators.

Materials and Methods
=====================

Bacterial strains and growth conditions
---------------------------------------

*Burkholderia pseudomallei* strains used in this study are listed in Table [1](#T1){ref-type="table"}. *E*. coli strains DH5α (Liss, [@B21]) and MACH1 (Invitrogen, Carlsbad, CA, USA) were used as general cloning strains, and DB3.1 (Invitrogen) for cloning with Gateway Vectors. RHO3 was used as a mobilizer strain for conjugation of plasmids from *E. coli* to *B. pseudomallei* (López et al., [@B23]). Bacterial strains were grown in Lennox LB (MO BIO Laboratories, Carlsbad, CA, USA) or LB without salt (10 g/L tryptone and 5 g/L yeast extract) at 37°C. Antibiotics were used at the following concentrations: 100 μg/mL ampicillin (Amp), 35 μg/mL kanamycin (Km), and 15 μg/mL zeocin (Zeo) for *E. coli* and 1,000 μg/mL Km and 2,000 μg/mL Zeo for *B. pseudomallei*. Antibiotics were purchased from Sigma (St. Louis, MO, USA) except Zeo which was from Invitrogen. The Δ*purM* strain Bp82 was grown in media supplemented with 0.6 mM adenine to ensure growth rates comparable to strain 1026b. RHO3 was grown in media containing 400 μg/mL diaminopimelic acid (DAP; LL-, DD-, and meso-isomers; Sigma). Induction of gene expression from *P~tac~* was achieved by adding 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG; Gold Biotechnology, St. Louis, MO, USA) to growth media.

###### 

***Burkholderia pseudomallei* strains used in this study**.

  Strain                           Description                                                                  Source
  -------------------------------- ---------------------------------------------------------------------------- --------------------------
  **Strain 1026b-based mutants**                                                                                
  1026b                            Clinical isolate, wild-type                                                  DeShazer et al. ([@B12])
  Bp319                            1026b Δ*penA*                                                                This study
  Bp409                            1026b Δ*tatABC*                                                              This study
  Bp420                            1026b Δ*penA* Δ*tatABC*                                                      This study
  Bp343                            1026b Δ*BPSS0945*                                                            This study
  Bp344                            1026b Δ*BPSS0944*                                                            This study
  Bp349                            1026b Δ*BPSS0948*                                                            This study
  Bp342                            1026b PenA R7K                                                               This study
  Bp421                            1026b PenA R8A                                                               This study
  **Strain Bp82-based mutants**                                                                                 
  Bp82                             1026b Δ*purM*                                                                Propst et al. ([@B29])
  Bp82.3                           Bp82 PenA C69Y                                                               This study
  Bp82.4                           Bp82 PenA S72F                                                               This study
  Bp82.5                           Bp82 PenA P167S                                                              This study
  Bp82.11                          Bp82 Δ*penA*                                                                 This study
  Bp82.14                          Km^r^; Bp82:Tn*7*T-*P~s12~*-FKM*-lox-BPSS0944*[^a^](#t1fn1){ref-type="fn"}   This study
  Bp82.15                          Km^r^; Bp82:Tn*7*T-*P~s12~*-FKM*-lox-BPSS0945*                               This study
  Bp82.16                          Km^r^; Bp82:Tn*7*T-*P~s12~*-FKM*-lox-BPSS0948*                               This study
  Bp82.21                          Km^r^; Bp82:Tn*7*T-LAC-FKM*-penA ^+^ [^b^](#t1fn2){ref-type="fn"}*           This study

^a^*Cloned genes are transcribed from the constitutive *B. thailandensis* ribosomal s12 gene promoter*.

^b^*Cloned penA gene is transcribed from the IPTG-inducible E. coli lactose operon/tryptophan hybrid promoter P~tac~*.

Isolation of mutants containing chromosomal deletion or point mutations
-----------------------------------------------------------------------

All deletion and allelic-exchange procedures were based on pEXKm5 (López et al., [@B23]; plasmids used in this study are listed in Table [2](#T2){ref-type="table"}) and were performed using previously described protocols. The desired chromosomal deletions were verified by colony PCR (Choi et al., [@B8]).

###### 

**Plasmids used in this study**.

  Designation                                                                    Description[^a^](#t2fn1){ref-type="fn"}                                                                                                                                                                    Source
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  **PLASMIDS FOR *penA* DELETION AND OVEREXPRESSION**                                                                                                                                                                                                                                       
  pUCP20                                                                         Ap^r^; Broad host-range cloning vector                                                                                                                                                                     West et al. ([@B38])
  pEXKm5                                                                         Km^r^; Allelic-exchange plasmid                                                                                                                                                                            López et al. ([@B23])
  pTNS3                                                                          Ap^r^; Tn*7* insertion helper plasmid                                                                                                                                                                      Choi et al. ([@B8])
  pUC18T-mini-Tn*7*T-Km-LAC                                                      Ap^r^ Km^r^; Tn*7* cassette vector with *P~tac~* and *lacI*^q^ for regulated expression of cloned genes                                                                                                    This study
  pPS2370                                                                        Ap^r^; pUCP20 with a 1,308 bp *penA* fragment (amplified with primers 1687 + 1712) inserted into *Sma*I site                                                                                               This study
  pPS2549                                                                        Ap^r^; pPS2370 with 291 bp *Nsi*I-*Pml*I fragment deleted from *penA*                                                                                                                                      This study
  pPS2550                                                                        Km^r^; 1,339 bp *Pvu*II fragment from pPS2549 was inserted into the *Sma*I site of pEXKm5                                                                                                                  This study
  pPS2605                                                                        Ap^r^ Km^r^; pCR2.1 with 1,230 bp *penA* fragment (amplified with primers 2003 + 2005)                                                                                                                     This study
  pPS2608                                                                        Ap^r^ Km^r^; pCR2.1 with the 1,261 bp *penA* fragment from pPS2605 (amplified with primers 2003 + 2004 to modify the 5^′^ region)                                                                          This study
  pPS2627                                                                        Ap^r^ Km^r^; pUC18T-mini-Tn*7*T-Km-LAC with the 1,266 bp *penA* fragment from pPS2608                                                                                                                      This study
  **PLASMIDS FOR *penA* PUTATIVE REGULATORY GENE DELETION AND OVEREXPRESSION**                                                                                                                                                                                                              
  pPS2609                                                                        Ap^r^ Km^r^; 1,043 bp SOEing PCR product using primer sets 2014 + 2015 and 2016 + 2017 was ligated into pCR2.1                                                                                             This study
  pPS2610                                                                        Ap^r^ Km^r^; 1,300 bp SOEing PCR product using primer sets 2010 + 2011 and 2012 + 2013 was ligated into pCR2.1                                                                                             This study
  pPS2611                                                                        Ap^r^ Km^r^; 1,239 bp SOEing PCR product using primer sets 2006 + 2007 and 2008 + 2009 was ligated into pCR2.1                                                                                             This study
  pPS2614                                                                        Km^r^; blunt ended 1,085 bp *Bst*XI fragment from pPS2609 ligated into *Sma*I site of pEXKm5                                                                                                               This study
  pPS2615                                                                        Km^r^; 1,316 bp *Eco*RI fragment from pPS2610 ligated into *Eco*RI site of pEXKm5                                                                                                                          This study
  pPS2616                                                                        Km^r^; 1,255 bp *Eco*RI fragment from pPS2611 ligated into *Eco*RI site of pEXKm5                                                                                                                          This study
  pUC18-mini-Tn7T-Gm-Gateway                                                     Ap^r^ Gm^r^; mini-Tn*7*T-Gm with GATEWAY cassette. GenBank accession number AY737004                                                                                                                       Choi et al. ([@B7])
  pPS2735                                                                        Ap^r^ Km^r^; pUC18T-mini-Tn*7*T-Km-*FRT* with *P~s12~*                                                                                                                                                     This study
  pPS2737                                                                        Ap^r^ Km^r^; Gateway-ready Tn*7* cassette vector with *s12* promoter toward insert (*Kpn*I-*Afe*I fragment containing 1,824 bp Gateway cassette from pPS1612 ligated into pPS2735 between *Kpn*I-*Stu*I)   This study
  pPS2745                                                                        Km^r^; Nested PCR with primers 2015 + 2016, then 2155 + 2156 for 1,051 bp fragment, cloned into pENTR-SD-D-TOPO                                                                                            This study
  pPS2746                                                                        Km^r^; Nested PCR with primers 2013 + 2010, then 2157 + 2158 for 1,056 bp fragment, cloned into pENTR-SD-D-TOPO                                                                                            This study
  pPS2747                                                                        Km^r^; Nested PCR with primers 2009 + 2006, then 2159 + 2160 for 1,456 bp fragment, cloned into pENTR-SD-D-TOPO                                                                                            This study
  pPS2748                                                                        Ap^r^ Km^r^; Gateway LR recombination reaction with pPS2737 + pPS2745                                                                                                                                      This study
  pPS2749                                                                        Ap^r^ Km^r^; Gateway LR recombination reaction with pPS2737 + pPS2746                                                                                                                                      This study
  pPS2750                                                                        Ap^r^ Km^r^; Gateway LR recombination reaction with pPS2737 + pPS2747                                                                                                                                      This study
  **PLASMIDS FOR ENGINEERING OF TAT-SIGNAL SEQUENCE MUTATIONS**                                                                                                                                                                                                                             
  pPS2674                                                                        Ap^r^ Km^r^; 740 bp of the 5^′^ region of *penA* gene amplified with primers 2010 + 2011 and cloned into pCR2.1                                                                                            This study
  pPS2613                                                                        Ap^r^ Km^r^; Mutagenic primer 2022 substituted AAG for CGC at bases 19-21 of *penA* in pPS2674 to provide a R7K substitution                                                                               This study
  pPS2618                                                                        Km^r^; 736 bp *Eco*RI fragment from pPS2676 ligated into *Eco*RI of pEXKm5                                                                                                                                 This study
  pPS2676                                                                        Ap^r^ Km^r^; Mutagenic primer 2076 substituted GC for CG at bases 22-23 of *penA* in pPS2674 to provide a R8A substitution                                                                                 This study
  pPS2678                                                                        Km^r^; 736 bp *Eco*RI fragment from pPS2676 ligated into *Eco*RI of pEXKm5                                                                                                                                 This study
  **PLASMIDS FOR ENGINEERING OF *penA* POINT MUTATIONS**                                                                                                                                                                                                                                    
  pPS2675                                                                        Ap^r^ Km^r^; Mutagenic primer 2075 mutated G to A at base 224 of *penA* to provide a C69Y substitution in pPS2674 sequence                                                                                 This study
  pPS2677                                                                        Km^r^; 736 bp *Eco*RI fragment from pPS2675 ligated into *Eco*RI of pEXKm5                                                                                                                                 This study
  pPS2712                                                                        Km^r^; 1,094 bp *Nru*I-*Hinc*II fragment (entire *penA*) from pPS2370 ligated into the *Sma*I site of pEXKm5                                                                                               This study
  pPS2721                                                                        Km^r^; Mutagenic primer 2136 mutated C to T at base 517 of *penA* to provide a P167S substitution using pPS2712 (pEXKm5-based)                                                                             This study
  pPS2722                                                                        Km^r^; Mutagenic primer 2137 C to T at base 233 of *penA* to provide a S72F mutation using pPS2712 (pEXKm5-based)                                                                                          This study
  **PLASMIDS FOR *tatABC* DELETION**                                                                                                                                                                                                                                                        
  pPS2612                                                                        Ap^r^; 1,038 bp Soeing PCR product using primer sets 2018 + 2019 and 2020 + 2021 ligated into pGem-T Easy (Promega, Madison, WI, USA)                                                                      This study
  pPS2617                                                                        Km^r^; 1,058 bp *Eco*RI fragment from pPS2612 ligated into *Eco*RI of pEXKm5                                                                                                                               This study

^a^*Ap, ampicillin; Km, kanamycin; Gm, gentamicin; *Ps12*, *B. thailandensis* ribosomal *s12* gene promoter*.

For construction of *penA* deletion mutants, PCR with primers 1687 + 1712 (PCR primers and mutagenic oligonucleotides are listed in Table [3](#T3){ref-type="table"}) and *Taq* polymerase (New England BioLabs, Ipswich, MA, USA) was used to amplify a 1,308-bp region containing the *BPSS0946* (*penA*) gene from 1026b chromosomal DNA. The gel-purified PCR fragment was cloned into the *Sma*I site of pUCP20 to yield pPS2370. This plasmid was then cleaved with *Nsi*I + *Pml*I, blunt ended with T4 DNA polymerase, followed by re-ligation. This procedure deleted a 291-bp *Nsi*I − *Pml*I fragment from the *penA* gene and resulted in pPS2549. A 1,339-bp *Pvu*II Δ*penA* fragment was excised from this plasmid and ligated into the *Sma*I site of pEXKm5 to create pPS2550. This plasmid was used to create Bp82.11 and Bp319 by transferring the plasmid-borne deletion alleles to either Bp82 or 1026b, respectively, via conjugation from RHO3.

###### 

**Primers used in this study**.

  Primer                             Sequence[^a^](#t3fn1){ref-type="fn"}^,^[^b^](#t3fn2){ref-type="fn"}^,^[^c^](#t3fn3){ref-type="fn"}^,^[^d^](#t3fn4){ref-type="fn"}   Source
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------
  **CLONING/DELETION**                                                                                                                                                   
  1687                               5^′^-**GGATCC**GACGAGAGCTGATACGCTAG                                                                                                 This study
  1712                               5^′^-**AAGCTT**ATACCGGCATCGTTTCGCTG                                                                                                 This study
  2003                               5^′^- GAATTCGATACCGGCATCGTTTCG                                                                                                      This study
  2004                               5^′^-GATATCAGCCGTTGACTTAGTTGGTATTTCCGGAATATCATGCTGGTTCCGAATAA TTTTGTTTAACTTTAAGA[[AGGA]{.ul}]{.ul}GATATAC                           This study
  2005                               5^′^-ACTTTAAGAAGGAGATATACATGAATCATTCTCCGTTGCGC                                                                                      This study
  2006                               5^′^-CAATCTCGACGGAGCACG                                                                                                             This study
  2007                               5^′^-[CTTGAATGCCCTGCAGATCTT]{.ul}GGCCGCTACAGATACGACAC^b^                                                                            This study
  2008                               5^′^-AAGATCTGCAGGGCATTCAAG                                                                                                          This study
  2009                               5^′^-GGTCATCGGGGACGAGTG                                                                                                             This study
  2010                               5^′^-CGAATAGCGGATGAGATCG                                                                                                            This study
  2011                               5^′^-[GTTGTCTCGAGCATGAGCAA]{.ul}GGATTTTCTGACCGCTTACG                                                                                This study
  2012                               5^′^-TTGCTCATGCTCGAGACAAC                                                                                                           This study
  2013                               5^′^-AATGGGCGATACGGTAACAG                                                                                                           This study
  2014                               5^′^-ACGAGCTTCCGAAATACACG                                                                                                           This study
  2015                               5^′^-ATCGAGACGATTCGTTCAGC                                                                                                           This study
  2016                               5^′^-CGAGCATCTCAAAATTCATCC                                                                                                          This study
  2017                               5^′^-[CGTGTATTTCGGAAGCTCGT]{.ul}TAATGGGCGATACGGTAACAG                                                                               This study
  2018                               5^′^- ATGAATCACGACCCGAACTG                                                                                                          This study
  2019                               5^′^- [CTTGCTCTCGTCCTCTTCCT]{.ul}ACGATCAGCAACACGATCAG                                                                               This study
  2020                               5^′^- AGGAAGAGGACGAGAGCAAG                                                                                                          This study
  2021                               5^′^- GACGAAGCTGCTGAACGTC                                                                                                           This study
  2041                               5^′^-AGATACGGCATCGGATTGAC                                                                                                           This study
  2042                               5^′^-GTCGCCGGCTGATTATTTC                                                                                                            This study
  2043                               5^′^-GCAACGCTTGTTTCAATACG                                                                                                           This study
  2044                               5^′^-GAAAGGCTCGGTCACGTTC                                                                                                            This study
  2045                               5^′^-AATTCGTCACACGAACATGC                                                                                                           This study
  2046                               5^′^-CGTCATTCCACCTTCCATTG                                                                                                           This study
  2047                               5^′^-AGGAGGTCTACCACCTGCAC                                                                                                           This study
  2048                               5^′^-TTTTGTTTGCCGCCATTC                                                                                                             This study
  2187                               5^′^-CGAGCTTTCGCTGTCCTATC                                                                                                           This study
  2188                               5^′^-[CGTGATCTTCGTGTCCTTGA]{.ul}GTTGTGTCATTGCGCTTCTC                                                                                This study
  2189                               5^′^-TCAAGGACACGAAGATCACG                                                                                                           This study
  2190                               5^′^-CCGGCAATTGATCGAACTC                                                                                                            This study
  2191                               5^′^-CGATCAACGTGATCTTCGTG                                                                                                           This study
  **MUTAGENIC PRIMERS**                                                                                                                                                  
  2022                               5^′^Phos/-GAATCATTCTCCGTTG *AAG* CGCTCGCTGCTCGTCGCAGC                                                                               This study
  2075                               5^′^Phos/-GCTTTCCCGTTCT *A* CAGCACATCCAAGATGATGC                                                                                    This study
  2076                               5^′^Phos/-GAATCATTCTCCGTTGCGC *GC* CTCGCTGCTCGTCGCAGC                                                                               This study
  2136                               5^′^Phos/-GCGCCGTGTTCAGCTCAG *A* CTCGCGGCGATCGAGC                                                                                   This study
  2137                               5^′^Phos/-AAAGCATCATCTTG *A* ATGTGCTGCAGAACTGG                                                                                      This study
  **REAL TIME PCR PRIMERS**                                                                                                                                              
  Bp23S-F                            5^′^-GTAGACCCGAAACCAGGTGA                                                                                                           Mima and Schweizer ([@B25])
  Bp23S-R                            5^′^-CACCCCTATCCACAGCTCAT                                                                                                           Mima and Schweizer ([@B25])
  2077                               5^′^-GTTCTGCAGCACATCCAAGA                                                                                                           This study
  2078                               5^′^-CGGTGTTGTCGCTGTACTGA                                                                                                           This study
  **CLONING**                                                                                                                                                            
  1687                               5^′^-**GGATCC**GACGAGAGCTGATACGCTAG                                                                                                 This study
  1712                               5^′^-**AAGCTT**ATACCGGCATCGTTTCGCTG                                                                                                 This study
  2010                               5^′^-AGGCTGGCTGTACTTGAACG                                                                                                           This study
  2011                               5^′^-CGGGCGATATTCTGATGTC                                                                                                            This study
  **TN7 INTEGRATION CONFIRMATION**                                                                                                                                       
  Tn*7*L                             5^′^-ATTAGCTTACGACGCTACACCC                                                                                                         Choi et al. ([@B7])
  BPGLMS1                            5^′^-GAGGAGTGGGCGTCGATCAAC                                                                                                          Choi et al. ([@B8])
  BPGLMS2                            5^′^-ACACGACGCAAGAGCGGAATC                                                                                                          Choi et al. ([@B8])
  BPGLMS3                            5^′^-CGGACAGGTTCGCGCCATGC                                                                                                           Choi et al. ([@B8])

^a^*Bold indicates a newly generated restriction enzyme cleavage site*.

^b^*Underline indicates overlapping sequence for SOEing PCR; a double underline indicates a ribosome binding site*.

^c^*Italics indicates introduced point mutations*.

^d^*Phos, 5^′^ phosphorylated oligonucleotide*.

For deletion of *tatABC,* splicing by overlap extension (SOEing) PCR was employed for engineering of deletion constructs. SOEing reactions consisted of separately amplifying two fragments, one using an "internal" primer with overlapping sequence with the internal primer from the other fragment. These bands were gel purified and 50 ng of each product was added to a new PCR reaction where it underwent PCR for five cycles (95°C for 60 s, 54°C 30 s, and 72°C for 60 s). At this point, the two non-overlapping primers were added and the reaction proceeded for another 30 cycles. Using in-house purified *Pfu* polymerase and primer sets 2018 + 2019 (amplifying a 537-bp *tatA* 5^′^ fragment) and 2020 + 2021 (amplifying a 501-bp *tatC* 3^′^ fragment), a 1,038-bp SOEing PCR product was generated to delete 1,527 bp from the *tatABC* gene cluster. This PCR product was ligated into pGem-T Easy (Promega; Madison, WI, USA) to create pPS2612. An *Eco*RI fragment was rescued from this plasmid and inserted into pEXKm5 to create pPS2617, which was used to create Bp409 and Bp420 by transferring the plasmid-borne deletions to either 1026b or Bp319 (1026b Δ*penA*), respectively. PCR using primers 2047 + 2048 was used to confirm the deletion.

Other genes located in the *penA* region of the chromosome were deleted using a SOEing PCR strategy and pCR2.1 ( Invitrogen) as TA cloning vector. The *BPSS0944* deletion construct was created using primer sets 2014 + 2015 and 2016 + 2017 to generate pPS2609, from which a *Bst*XI fragment was excised and inserted into the *Sma*I site of pEXKm5 to yield pPS2614. The *BPSS0945* deletion construct was generated using primer sets 2010 + 2011 and 2012 + 2013 to create pPS2610, from which an *Eco*RI fragment was excised and inserted into the *Eco*RI site of pEXKm5 to yield pPS2615. The *BPSS0948* deletion construct was created using primer sets 2006 + 2007 and 2008 + 2009 to generate pPS2611, from which an *Eco*RI fragment was excised and inserted into the *Eco*RI site of pEXKm5 to yield pPS2616. The plasmid-borne deletion alleles were transferred to the *B. pseudomallei* 1026b genome which resulted in strains Bp343, Bp344 and Bp349, respectively. Deletions were verified by colony PCR using primer sets 2045 + 2446, 2041 + 2042 and 2043 +  2044, respectively.

Chromosomal *penA* point mutations were engineered using the QuikChange Multi Kit (Stratagene, La Jolla, CA, USA), 5^′^-phosphorylated mutagenic oligonucleotides, and plasmid DNA templates. Mutagenic oligonucleotide 2075 was used with pPS2674 to create pPS2675 for the PenA C69Y mutation. A 736-bp *Eco*RI fragment from pPS2675 was then ligated into the *Eco*RI site of pEXKm5 to construct pPS2677. Plasmid pPS2712 was created as a platform for other mutations by ligating the *Nru*I--*Hinc*II containing *penA* fragment from pPS2676 into the *Sma*I site of pEXKm5. Employing pPS2712 template DNA, mutagenic oligonucleotides 2136 and 2137 were used separately to create pPS2721 and pPS2722 carrying PenA P167S and PenA S72F substitutions, respectively. Allelic exchange was carried out by conjugal transfer of pPS2677 (C69Y), pPS2721 (P167S), and pPS2722 (S72F) from RHO3 into Bp82. Mutations were verified by PCR amplifying and sequencing the region containing the expected mutation. TAT-signal sequence mutations were generated using a similar strategy. The R7K mutation was engineered using mutagenic oligonucleotide 2022 and pPS2674 to create pPS2613. The 736-bp *Eco*RI fragment from this plasmid was ligated into pEXKm5 to yield pPS2618. The R7K allele contained on this fragment was transferred to the 1026b genome which created Bp342. The mutagenic oligonucleotide 2076 was used with pPS2674 to engineer pPS2676 to create an R8A mutation. The 736-bp *Eco*RI fragment was excised from this plasmid and ligated into pEXKm5 to create pPS2678. The R8A allele contained on this fragment was transferred to the 1026b genome which created Bp421. The presence of the desired point mutations on plasmids and the genome was verified by DNA sequencing.

Gene complementation and overexpression using single-copy, chromosomally integrated mini-Tn*7* vectors
------------------------------------------------------------------------------------------------------

The mini-Tn*7* system was used for introducing site-specific, stable insertions into the *B. pseudomallei* genome for purposes of gene complementation or overexpression (Choi et al., [@B8]). Tn*7* transposition was achieved by tri-parental mating involving RHO3 harboring the mini-Tn*7* vector, RHO3 containing the helper plasmid pTNS3 and the *B. pseudomallei* recipient strain, as previously described (Choi et al., [@B6]). Integration events were verified using primers Tn*7*L and either BPGLMS1, BPGLMS2, or BPGLMS3 (Choi et al., [@B8]). All Tn*7* mutants retained and used for further experimentation had insertions at the *glmS*2-associated Tn*7* insertion site.

For regulated *penA* expression and overproduction, the gene was PCR amplified from pPS2370 using primers 2003 + 2005 and *Pfu* polymerase and the 1,230-bp PCR product cloned into pCR2.1 (Invitrogen) to yield pPS2605. An optimized ribosome binding site (RBS) was introduced upstream of *penA* to create pPS2608 by PCR amplifying the *penA* region of pPS2605 with primers 2003 + 2004 and cloning the resulting 1,261 bp fragment into pCR2.1. (The amplicon was expected to be 1,295 bp but the 5^′^ end was truncated by 34 bp which did not affect the integrity of the *penA* gene.) An expression construct where *penA* was transcribed from the inducible *P~tac~* was obtained by cloning the 1,300-bp *Eco*RI fragment from pPS2608 into pUC18T-mini-Tn*7*T-Km-LAC to create pPS2627. The mini-Tn*7* expression cassette from pPS2627 was integrated into the genome of Bp82 at the *glmS*2-associated Tn*7* integration site to form Bp82.21.

Constitutive expression of genes was achieved from chromosomally integrated mini-Tn*7* elements where the respective genes were transcribed from the *B. thailandensis s12* promoter (Choi et al., [@B8]). Nested PCR and *Pfu* polymerase was used to PCR amplify *BPSS0944* (primers 2015 + 2016 and 2155 + 2156)*, BPSS0945* (primers 2010 + 2013 and 2157 + 2158), and *BPSS0948* (primers 2006 + 2009 and 2159 + 2160) from strain 1026b genomic DNA. Each PCR began with three cycles using only the outside set (listed first) then the inner set (listed second) was added for 30 more cycles. Inner primers were designed for use with the pENTR/SD/D-TOPO cloning vector (Invitrogen, Carlsbad, CA, USA), which provides a RBS and directionality, and created pPS2745, pPS2746, and pPS2747, respectively. These plasmids then underwent the Gateway LR recombination reaction (Invitrogen) with pPS2737, a mini-Tn*7* vector which enables constitutive expression from the *B. thailandensis s12* promoter (this promoter is directed toward the Gateway recombination cassette). To create pPS2737 the 1,824-bp Gateway-cassette-containing the *Kpn*I-*Afe*I fragment from pUC18-mini-Tn*7*T-Gm-Gateway was ligated into pPS2735 between the *Kpn*I and *Stu*I sites. This Gateway-compatible mini-Tn*7* element was used to create pPS2748, pPS2749, and pPS2750 for constitutive expression of *BPSS0944, BPSS0945,* and *BPSS0948*, respectively. The mini-Tn*7* elements contained on these plasmids were individually inserted at the *glmS*2 site of Bp82 with the help of pTNS3 to create Bp82.14, Bp82.15, and Bp82.16.

MIC determinations
------------------

MICs were determined following general procedures recommended by the Clinical and Laboratory Standards Institute ([@B9]). However, since Δ*tatABC* mutants do not grow well in the presence of salts LB without salt was substituted for Mueller--Hinton Broth. MICs for ampicillin, carbenicillin, and BAL30072 (obtained from Basilea Pharmaceutica, Basel, Switzerland) were determined by the two-fold broth microdilution technique. Etest strips were used to determine MICs for amoxicillin, amoxicillin--clavulanic acid, ceftazidime, imipenem, meropenem, and piperacillin according to manufacturer's instructions (AB BioMérieux, Marcy l'Etoile, France). When needed, IPTG was added to media at a final concentration of 1 mM. The MICs were recorded after incubation at 37°C for 18--24 h.

Quantification of *penA* transcript levels
------------------------------------------

Overnight cultures were subcultured into LB medium, grown to an OD~600 nm~ of 0.5 and RNA was extracted with the RNeasy Protect Bacteria Mini Kit (Qiagen, Valencia, CA, USA). cDNA was synthesized using the SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen) and quantified using SYBR GreenER qPCR SuperMix for iCycler Instruments (Invitrogen) and the Bio-Rad iQ5 iCycler. The Bp23S-F + Bp23S-R primer set was used for the 23s rRNA housekeeping gene for data normalization and primers 2077 + 2078 were used to quantify the *penA* transcript. Data analyses were performed using the iCycler software. For induction studies with both wild-type and the mutants with constitutive regulatory gene expression or deletion several methods were employed. For salt stress testing, strains were grown in media with 150 mM NaCl or no NaCl according to Pumirat et al. ([@B30]). For testing induction by β-lactams at sub-inhibitory levels, strains were subcultured into LB with 4-fold lower than MIC concentrations of either ceftazidime or carbenicillin until an OD~600 nm~ of 0.5 was reached. Induction was also tested with fourfold higher than MIC concentrations of ceftazidime, carbenicillin, imipenem, or penicillin G (2,000 μg/mL for penicillin G) by growing in LB to an OD~600 nm~ of 0.5, then adding β-lactams and shaking for an additional 2 h before RNA extraction, according to Trépanier et al. ([@B34]).

Protein techniques
------------------

*Burkholderia pseudomallei* cells were fractionated into periplasm and spheroplastic protein fractions (cytosol and membranes) using the PeriPreps^™^ Periplasting Kit (Epicentre Biotechnologies, Madison, WI, USA) Cells were grown overnight and diluted 1:100 at 37°C in LB medium without NaCl until an optical density of 0.7 (600 nm) was reached. The kit was used according to manufacturer's protocols, including extended incubation times and higher concentrations of lysozyme (25 μg/reaction), as recommended for hardier bacteria.

*Escherichia coli* Origami 2 *DE3* cells (Novagen, Madison, WI, USA) expressing *bla*~penA~ minus the first 90 nucleotides (30 amino acids) which encode the N-terminal signal sequence were subcloned in the pET24a(+) vector (Stratagene) and used for protein production and purification. The PenA β-lactamase was extracted from *E. coli* and purified using preparative isoelectric focusing. After verification of purity by SDS PAGE, 3.0 mg of PenA was sent to New England Peptide (Gardner, MA, USA) where the polyclonal anti-PenA antibodies were raised in rabbits. The antibodies were subsequently isolated from serum using a Protein G column (GE Healthcare Life Sciences, Piscataway, NJ, USA) purification according to the manufacturer's instructions.

For Western blots, protein samples were separated on NuPAGE^®^ 4--12% Bis--Tris polyacrylamide gels (Invitrogen) alongside Precision Plus Protein Prestained Dual Color Standards (Bio-Rad, Hercules, CA, USA). A goat anti-Rabbit IgG alkaline phosphatase-conjugated antibody (Sigma) was used as a secondary antibody and SIGMAFAST^™^ BCIP^®^/NBT tablets (Sigma) as a detection reagent according to the manufacturer's protocol.

Results
=======

The role of of penA in β-lactam resistance
------------------------------------------

To assess whether Bp82 and its parent 1026b could interchangeably be used for PenA characterization experiments, the susceptibilities of these strains to various β-lactams were tested. Observable differences in the susceptibilities of these two strains for any of the beta-lactams and clavulanic acid tested (Table [4](#T4){ref-type="table"}) were not seen, thereby validating the use of Bp82 in experiments otherwise not feasible under Select Agent regulations. Deletion of the *penA* gene from 1026b (strain Bp319) and Bp82 (strain Bp82.11) caused a significant (≥4-fold) decrease in the susceptibilities for six of nine β-lactams tested, and ≥16-fold for three of them (ampicillin, amoxicillin, and carbenicillin; Table [4](#T4){ref-type="table"}). Likewise, up-regulation of *penA* by single-copy expression from the IPTG-inducible *P~tac~* (Bp82.21) significantly increased the MIC for seven of the eight β-lactams tested with meropenem showing only slight change. (Amoxicillin could not be tested as the resistance level for the wild-type was already beyond detection.) Quantitative real time PCR experiments showed that in the *P~tac~*-*penA* strain (Bp82.21) *penA* transcript levels were 36-fold higher when compared to transcript levels observed in the wild-type strain (data not shown). This increase in transcript levels corresponds to the observed increases in resistance to all β-lactams. These experiments demonstrated that although PenA is a clinically significant β-lactam resistance mechanism, it affects some β-lactams more than others. While mutations in *penA* can significantly affect the utility of ceftazidime and amoxicillin + clavulanic acid, the enzyme has a lesser effect on the activity of carbapenems and novel experimental drugs such as BAL30072.

###### 

**β-lactam susceptibilities of PenA, TAT-signal sequence, and TAT secretion apparatus mutants**.

                                               MIC (μg/mL)                                                                                       
  --------- ---------------------------------- ---------------------------------- -------- --------- ------ -------- -------- ------ ----------- -------
  1026b     None                               ≥256[^b^](#t4fn2){ref-type="fn"}   3        256       8      1024     3        1.5    0.75        0.065
  Bp82      None[^c^](#t4fn3){ref-type="fn"}   ≥256                               3        128       8      1024     3        1.5    0.75        0.031
  Bp319     Δ*penA*                            6                                  3        8--16     2      32       2        0.25   0.75        0.016
  Bp82.11   Δ*penA*                            ND                                 3        ND        ND     ND       ND       ND     ND          ND
  Bp82.21   Tn*7*-*penA* + IPTG                ≥256                               16       2048      64     \>4096   32       16     1.5         0.25
  Bp82.3    PenA C69Y                          6                                  3        4--8      6--8   32--64   ≥256     0.19   0.75        0.031
  Bp82.4    PenA S72F                          ≥256                               12--16   64--128   8      512      3        1--2   0.75        0.031
  Bp82.5    PenA P167S                         6                                  3        4--8      4      32--64   16--24   0.19   0.5--0.75   0.031
  Bp409     Δ*tatABC*                          4--6                               3        4--8      3      16--32   1.5      0.19   0.5         0.016
  Bp420     Δ*penA* Δ*tatABC*                  4                                  3        4         2      16       1        0.25   0.05        0.016
  Bp342     PenA R7K                           ≥256                               3        128       8      1024     3        2      0.75        0.031
  Bp421     PenA R8A                           8                                  3        8         2      32       1        0.25   0.5         0.031

^a^*Bp319, Bp342, Bp409, Bp420, and Bp421 were derived from 1026b; Bp82.11 and Bp82.21 were derived from Bp82*.

^b^*≥256, the detection limit is 256 μg/mL*.

^c^*No *penA* or *tat* mutation but strain is a 1026b Δ*purM* derivative*.

*ND, not done*.

penA mutations are responsible for clinically significant ceftazidime and amoxicillin + clavulanic acid resistance
------------------------------------------------------------------------------------------------------------------

Previous studies identified several *penA* mutations in clinical and laboratory isolates that led to clinically significant ceftazidime or clavulanic acid resistance. Specifically, a C69Y substitution caused high-level ceftazidime resistance (Sam et al., [@B31]), a P167S substitution medium-level ceftazidime resistance (Tribuddharat et al., [@B35]), and a S72F mutation resistance to clavulanic acid (Tribuddharat et al., [@B35]). To assess whether these mutations alone were sufficient to cause the observed resistance phenotypes, they were engineered into the *penA* gene of strain Bp82 resulting in expression of a mutated PenA from the native *penA* promoter. Susceptibility studies revealed that the C69Y (Bp82.3) and P167S (Bp82.5) point mutations caused significant increases in ceftazidime resistance of ≥85- and 5- to 8-fold, respectively (Table [4](#T4){ref-type="table"}). These changes are clinically significant since the ceftazidime susceptibility, intermediate and resistance breakpoints are defined as MICs of ≤8, 16, and ≥32 μg/mL, respectively. The C69Y mutation sensitized strains to other β-lactams such as amoxicillin, ampicillin, carbenicillin, and imipenem but not amoxicillin + clavulanic acid, piperacillin, meropenem, and BAL30072, whose MICs were already at low levels. The S72F point mutation caused a four-fold increase in resistance to amoxicillin + clavulanic acid in the resulting strain Bp82.4 and did not cause any changes in susceptibility to other β-lactams.

PenA is secreted via the TAT system
-----------------------------------

Analysis of the amino-terminal PenA amino acid sequence revealed the presence of a putative TAT-signal sequence indicating that it may be a TAT secreted protein (Figure [1](#F1){ref-type="fig"}). To test this notion, the two signature arginine residues at positions 7 and 8 were changed to a lysine or alanine, respectively. MIC determinations revealed that disruption of the TAT-signal sequence by an R7K mutation (Bp342) did not affect PenA activity. This is in accordance with previous studies which have shown that mutation of the first arginine to a lysine can either have little effect or be completely inhibitory, depending on the rest of the signal sequence (Stanley et al., [@B32]). However, an R8A substitution (Bp421) completely abrogated PenA activity, consistent with PenA being a TAT secreted enzyme. This notion was further supported by the finding that a *tatABC* deletion mutant (Bp409) exhibited a susceptibility profile similar to those of the R8A substitution (Bp421) and Δ*penA* deletion strains (Bp319 and Bp82.11). As expected then, a Δ*penA* Δ*tatABC* double mutant (Bp420) was most susceptible to PenA substrates.

Cellular localization of PenA
-----------------------------

We next attempted to localize the PenA protein in the cell envelope using Western blot analysis and polyclonal α-PenA antibodies. Using this method, PenA could not be localized to the periplasmic fraction but rather only to the spheroplastic fraction which contains both cytosolic and membrane proteins. Multiple attempts at isolation of PenA from the periplasmic fraction employing other fractionation methods such as chloroform (Ames et al., [@B1]) or magnesium chloride (Imperi et al., [@B18]) extraction yielded the same results. Western blot analysis of the spheroplastic fraction (Figure [2](#F2){ref-type="fig"}) showed the mature 27 kDa PenA protein is seen only in an extract derived from wild-type 1026b (lane 5). In contrast, the unprocessed 31 kDa PenA protein was observed in extracts from the R8A (lane 1) and Δ*tatABC* (lane 2) mutants Bp421 and Bp409, respectively. A mixture of mature and unprocessed PenA was seen in the R7K mutant Bp342 extract with the majority being the mature protein (lane 3). As expected, no PenA protein was observed in the extract from the Δ*penA* mutant Bp319 (lane 4). This experiment provides biochemical evidence for PenA processing only in 1026b and the R7K mutants, both of which secrete active PenA via the TAT system as judged by β-lactam susceptibility assays. All other strains are susceptible to β-lactams.

![**PenA is a TAT secreted protein**. Spheroplastic proteins were analyzed by Western blot using anti-PenA polyclonal antibodies. The arrows point to the expected unprocessed (31 kDa) and processed (27 kDa) forms of PenA. Lanes: 1, R8A TAT-signal sequence mutant; 2, Δ*tatABC* mutant; 3, R7K TAT signal sequence mutant; 4, Δ*penA* mutant; 5, wild-type 1026b; M, molecular weight markers (two proteins of the 10- to 250-kDa Precision Plus Protein Dual Color Standards from Bio-Rad, Hercules, CA, USA).](fmicb-02-00139-g002){#F2}

Local regulators are not involved in regulation of *penA* gene expression
-------------------------------------------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, the *B. pseudomallei* *penA* region encodes two LysR-type transcriptional regulators and a putative peptidase. Since chromosomal β-lactamase gene expression was shown to be regulated by products of adjacent regulatory genes in several bacteria, including *B. cepacia* (Trépanier et al., [@B34]), the structural genes encoding for these regulators were either deleted or overexpressed and their effects on PenA transcription and activity assessed by either qRT-PCR or MIC determinations. Carbenicillin was used as a "sentry" β-lactam for assessing PenA activity by MIC experiments because it is one of the best PenA substrates (Table [4](#T4){ref-type="table"}). MIC determinations showed that neither deletion of putative regulators (Bp343 and Bp349 nor constitutive expression of the regulators (Bp82.14 and Bp82.16) affected PenA activity (data not shown). The same observations were made when ceftazidime was used in susceptibility assays instead of carbenicillin. Likewise, deletion (Bp344 and Bp82.31) or overexpression (Bp82.15) of the putative peptidase gene upstream of *penA* had no effect on PenA activity (data not shown). Lastly, since bacterial β-lactamase gene expression can either be subject to substrate induction or influenced by environmental factors such as salts (Pumirat et al., [@B30]), MIC determinations were performed in the presence or absence of substrate and salt. However, presence of ceftazidime, carbenicillin, or high salt and the absence salt had no apparent effect on β-lactam susceptibilities. qRT-PCR assays supported the MIC data, with no change in *penA* expression levels observed between controls and strains treated with ceftazidime, carbenicillin, imipenem, penicillin G, or high salt (data not shown).

Discussion
==========

The data presented in this study employing isogenetic mutants in a defined genetic background confirm that PenA is a major β-lactam resistance factor in *B. pseudomallei*. Increased expression of *penA* conferred increased resistance levels to the majority of β-lactams tested. Conversely, *penA* deletion resulted in susceptibility to all β-lactams tested. Furthermore, clinically observed *penA* mutations were responsible for the altered β-lactam substrate spectrum of the enzyme and consequently the new resistance profile. Point mutations near the active site are the most common reason for substrate profile shifting because they accommodate different side chains of various β-lactams by either changing the active site steric properties or locations of the actual active residues (Drawz and Bonomo, [@B13]). Complete shifts in substrate profiles have been previously documented, such as with a mutant gram negative TEM-1 β-lactamase showing increased ceftazidime hydrolysis but decreased activity against ampicillin (Venkatachalam et al., [@B37]). The good news is that the *B. pseudomallei* C69Y PenA mutation sensitizes the cell to other β-lactams thus possibly enabling new therapeutic strategies. Additionally, our studies showed that of all β-lactams tested meropenem is the only β-lactam not affected by *penA* mutations and overproduction, and thus the superior β-lactam antibiotic for melioidosis treatment with regard to potential emergence of PenA β-lactamase mutants. Unfortunately, current costs limit use of meropenem in many clinical settings, especially resource poor areas of the world (Cheng et al., [@B4]).

The mutants created and analyzed in this study did not precisely mimic previously documented mutants. In all cases, our strains had an equal or lower resistance level. This may simply be due to variations in MIC methodologies, which can change the measurements significantly (Wuthiekanun et al., [@B41], or *B. pseudomallei* strain variability that may affect resistance patterns (Thibault et al., [@B33]). Using the S72F clinical mutant as an example, two groups determined the MIC of the parental strain 392a and its mutant, 392f. The first group showed a 16-fold increase in amoxicillin--clavulanic acid resistance (Godfrey et al., [@B14]) but the other group only showed a two-fold increase (Tribuddharat et al., [@B35]). These numbers are significantly different from one another. The susceptibilities observed with our isogenetic Bp82 derivatives fell between the two previously reported set of numbers at 4- to 5- fold. Another potential cause for inconsistency was that some of the published experiments cloned the mutant *penA* gene and expressed it in an unrelated bacterium, *E. coli*, from a high-copy number plasmid (Ho et al., [@B16]; Tribuddharat et al., [@B35]). Our data showed that increased expression of *penA* from a single-copy, chromosomally inserted expression element with a strong inducible promoter can change the profile from susceptible to resistant. A high-copy number plasmid will obviously lead to higher gene expression and consequently high resistance levels. Additionally, other cellular factors, including outer membrane permeability, can affect the efficacy of resistance mechanisms. For the P167S mutation, Tribuddharat et al. ([@B35]) showed a 16-fold increase in ceftazidime resistance in *B. pseudomallei*, but only a two-fold change in an *E. coli* strain expressing recombinant *penA* genes.

Besides playing a crucial role in the export of virulence factors in many bacteria (De Buck et al., [@B11]), the TAT system has previously been shown to be required for the export of β-lactamases in *Mycobacterium smegmatis* (McDonough et al., [@B24]). Through deletion of the *tatABC* operon and mutation of a crucial arginine residue of the putative TAT-signal sequence of *B. pseudomallei* PenA, we showed that PenA is indeed a TAT secreted enzyme. The exact cellular location of PenA β-lactamase could not be pinpointed. Various periplasmic extraction techniques failed to localize the enzyme to the periplasm but rather indicated that it is localized in the spheroplastic compartments of the cell which encompasses the cytosol and the membranes. Since a secreted enzyme is unlikely to be localized in the cytosol this experimental evidence points to the fact that PenA may be a membrane-associated enzyme. This is in agreement with earlier findings by Livermore et al. ([@B22]) who demonstrated that after sonication and centrifugation, the vast majority of β-lactamase activity was present in the membrane fraction. Membrane association of β-lactamases is not common but has been documented. The first account of a membrane-associated β-lactamase in Gram negative bacteria was from work with *Moraxella catarrhalis* (Bootsma et al., [@B2]). In this case it was hypothesized that the gene was a lipoprotein of Gram positive origin, as membrane association in Gram positive bacteria had been previously observed. This is unlikely the case for PenA because *penA* has 70% GC content, comparable to the overall genome (68%). How *B. pseudomallei* PenA could become membrane associated is unclear since there is no evidence of the enzyme being a lipoprotein.

Further evidence for TAT secretion was obtained by analyzing the PenA processing. Tullman-Ercek et al. ([@B36]) describe the processing of TAT-signal sequences and the cleavage of their amino-termini upon passing through the inner membrane, using MdoD as an example. The authors describe a hydrophobic region before the processing site determined to be an AXA motif. A comparative analysis of the amino-termini of MdoD (MDRRRFKGSMAMAAVCGTSGASLFSQAAFA) and PenA (MNHSPLRRSLLVAAISTPLIGACAOLRGQAKNVAAA) at <http://expasy.org/tools/protscale.html> using the Kyte and Doolittle hydrophobicity algorithm revealed that the two sequences exhibited a similar hydrophobicity profile and comparable predicted processing sites (underlined AFA in MdoD and AAA in PenA). Using this information, we calculated that the molecular mass of PenA changes from 31 to 27 kDa after processing. Bands corresponding to these sizes were seen observed using Western blot analysis (Figure [2](#F2){ref-type="fig"}).

Some β-lactamase genes require LysR regulatory factors for expression, with or without a β-lactam inducer. Trépanier et al. ([@B34]) showed that the *penA* gene from *B. cepacia* was regulated by a LysR-family regulator encoded by the divergently transcribed *penR* gene when expressed from plasmids in *E. coli*. PenA β-lactamase gene expression was not only regulated by PenR but was also inducible in the presence of imipenem in this system. A gene, *BPSS0948*, homologous to *B. cepacia* *penR* is found in *B. pseudomallei* downstream of *penA* (Figure [1](#F1){ref-type="fig"}). An additional LysR-family regulator encoding gene, *BPSS0944*, is located upstream of *penA*, but it has less sequence homology to *penR* and is separated from *penA* by a putative peptidase gene. Our analyses involving gene deletions, induction experiments, as well as growing cells under conditions such as salt stress (Pumirat et al., [@B30] that may trigger β-lactamase induction showed that neither the LysR-type regulators BPSS0944 and BPSS0948 nor the putative peptidase encoded by *BPSS0945* are involved in regulation of *penA* expression in *B. pseudomallei* strain 1026b, at least not under the experimental conditions employed during these studies. Although many chromosomal β-lactamases are inducible, others are constitutively expressed (Neu and Chin, [@B27]; Jacoby and Bush, [@B19]). When multiple β-lactamases are present in a bacterial strain, they can be subject to complex regulation, including co-regulation with penicillin binding protein 2 (Hackbarth and Chambers, [@B15]; Naas et al., [@B26]). In this context it is noteworthy that by analysis of clinical strains obtained from patients that failed ceftazidime therapy and studies of recreated 1026b-based mutants we and others recently identified deletion of a *B. pseudomallei* PBP3 homolog as a mechanism causing high-level ceftazidime resistance (Chantratita et al., unpublished observations).

Definition of the molecular basis of resistance mechanisms for clinically significant β-lactams forms the basis for design of diagnostic tools that allow rapid detection of emergence of resistance and thus redirection (clinical settings) or initiation (biodefense) of proper melioidosis therapy or prophylaxis.
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